{"filing":{"accession_number":"0001193125-26-350537","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"apvo-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-20260814.htm"},"events":[{"id":27753,"run_id":25327,"accession_number":"0001193125-26-350537","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing Aptevo's financial results for the quarter ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes Q2 2026 financial position (cash and cash equivalents of $9.8 million) and operational updates on clinical progress, executive appointments, and strategic collaborations. The Item 2.02 classification and attached press release (Exhibit 99.1) are the hallmarks of an earnings release disclosure.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29418,"accession_number":"0001193125-26-350537","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Aptevo's financial results for the quarter ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes Q2 2026 financial position (cash and cash equivalents of $9.8 million) and operational updates on clinical progress, executive appointments, and strategic collaborations. The Item 2.02 classification and attached press release (Exhibit 99.1) are the hallmarks of an earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:11:39.806017+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29418,"accession_number":"0001193125-26-350537","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Aptevo's financial results for the quarter ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes Q2 2026 financial position (cash and cash equivalents of $9.8 million) and operational updates on clinical progress, executive appointments, and strategic collaborations. The Item 2.02 classification and attached press release (Exhibit 99.1) are the hallmarks of an earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:11:39.806017+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-08-14"}]}